These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 8800720)

  • 1. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.
    George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T
    J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
    Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
    Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients.
    Rose EA; Pepino P; Barr ML; Smith CR; Ratner AJ; Ho E; Berger C
    J Heart Lung Transplant; 1992; 11(3 Pt 2):S120-3. PubMed ID: 1622990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation.
    Loh E; Bergin JD; Couper GS; Mudge GH
    J Heart Lung Transplant; 1994; 13(2):194-201. PubMed ID: 8031799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease.
    Kerman RH; Susskind B; Kerman D; Lam M; Gerolami K; Williams J; Kalish R; Campbell M; Katz S; Van Buren CT; Frazier H; Radovancevic B; Fife S; Kahan B
    J Heart Lung Transplant; 1998 Aug; 17(8):789-94. PubMed ID: 9730428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database.
    Rossano JW; Morales DL; Zafar F; Denfield SW; Kim JJ; Jefferies JL; Dreyer WJ
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):694-9, 699.e1-2. PubMed ID: 20537356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation.
    Lavee J; Kormos RL; Duquesnoy RJ; Zerbe TR; Armitage JM; Vanek M; Hardesty RL; Griffith BP
    J Heart Lung Transplant; 1991; 10(6):921-9; discussion 929-30. PubMed ID: 1756157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients.
    Xydas S; Yang JK; Burke EM; Chen JM; Addonizio LJ; Mital SR; Itescu S; Hsu DT; Lamour JM
    J Heart Lung Transplant; 2005 Sep; 24(9):1289-96. PubMed ID: 16143247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function.
    Leech SH; Mather PJ; Eisen HJ; Pina IL; Margulies KB; Bove AA; Jeevanandam V
    Clin Transplant; 1996 Dec; 10(6 Pt 2):639-45. PubMed ID: 8996758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
    Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
    J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry.
    Donaldson PT; Thomson LJ; Heads A; Underhill JA; Vaughan RW; Rolando N; Williams R
    Transplantation; 1995 Nov; 60(9):1016-23. PubMed ID: 7491675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart transplantation across antibodies against human leukocyte antigen and ABO-post-transplant follow-up of donor reactive antibodies.
    Bućin D; Johansson S; Lindberg LO
    Xenotransplantation; 2006 Mar; 13(2):101-4. PubMed ID: 16623800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch.
    Wright EJ; Fiser WP; Edens RE; Frazier EA; Morrow WR; Imamura M; Jaquiss RD
    J Heart Lung Transplant; 2007 Nov; 26(11):1163-9. PubMed ID: 18022083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of panel-reactive antibody positivity on graft rejection before or after kidney transplantation.
    Lee KW; Kim SJ; Lee DS; Lee HH; Joh JW; Lee SK; Oh HY; Kim DJ; Kim YG; Huh WS; Oh WI; Lee BB
    Transplant Proc; 2004 Sep; 36(7):2009-10. PubMed ID: 15518726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group.
    Jarcho J; Naftel DC; Shroyer TW; Kirklin JK; Bourge RC; Barr ML; Pitts DG; Starling RC
    J Heart Lung Transplant; 1994; 13(4):583-95; discussion 595-6. PubMed ID: 7947874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
    Aubert V; Venetz JP; Pantaleo G; Pascual M
    Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.